🇺🇸 FDA
Patent

US 11407820

Modulating the alternative complement pathway

granted A61KA61K38/00A61K38/1709

Quick answer

US patent 11407820 (Modulating the alternative complement pathway) held by The Regents of the University of Colorado expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado
Grant date
Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K38/00, A61K38/1709, A61K38/177, A61P